New Insights into Recurrent Bacterial Vaginosis Infections

Australian researchers have discovered two factors contributing to recurrent bacterial vaginosis (BV), a prevalent sexual health issue impacting around one in four women worldwide.

Bacterial vaginosis, or BV for short, arises from an imbalance in the natural vaginal flora, where beneficial bacteria decline, allowing other mixed bacteria to proliferate.

In a significant study published last March, it was revealed that BV could be sexually transmitted from men to women. This breakthrough came when researchers found that simultaneously treating women and their male partners with antibiotics reduced the recurrence of BV by over 60%.

Now, a follow-up study aims to address why approximately 20% of women treated alongside their partners still experience BV. This research, published in The Lancet Obstetrics, Gynaecology & Women’s Health, involved 188 couples. The women were prescribed a week-long regimen of oral antibiotics, while the men received both oral and topical antimicrobials.

The findings indicated two primary reasons for recurring BV: the persistence of the condition despite antibiotic treatment and the possibility of re-infection from partners.

According to Dr. Lenka Vodstrcil, a senior research fellow involved in the study, around two-thirds of the women returned to a healthy vaginal microbiome characterized by an abundance of Lactobacilli bacteria shortly after completing their treatment. However, the remaining third showed signs that they might not have completely cleared their BV before resuming sexual activity, which made them nearly three times more likely to experience recurrence within four weeks.

This understanding of persistent infections is essential for developing improved treatment strategies. BV can often be asymptomatic, yet can lead to symptoms like vaginal itching and discomfort. It’s crucial to address this condition, as it heightens the risk of other infections and is linked to pregnancy complications.

The researchers believe this study might be the largest of its kind, focusing on heterosexual couples receiving concurrent treatment for BV. They noted that persistence and reinfection are distinct but potentially overlapping factors in recurring BV cases.

Among the female participants, 30% used an intrauterine device, which the study suggested could contribute to the persistence of BV post-treatment. However, further research is necessary to confirm this link.

Going forward, the scientists plan to explore longer treatment durations and combinations of antibiotics. Dr. Vodstrcil expressed a desire to minimize the frequency of antibiotics women need to take, which has been alarmingly high in the past.

Professor Catriona Bradshaw, another senior author, emphasized the need for more tailored treatment strategies aimed at preventing both re-infections and the persistence of BV bacteria. She noted that while the study’s participants reflected the diversity of urban Australia, its conclusions may not apply to populations in lower-income nations or other regions facing high BV prevalence.